Tag - LNTH

Developments

Lantheus, POINT get FDA fast track for mCRPC

The FDA granted Lantheus Holdings (NASDAQ:LNTH) and POINT Biopharma (NASDAQ:PNT) fast track designation for 177Lu-PNT2002 for the treatment of metastatic castration resistant prostate cancer (mCRPC). PNT2002 is an...

April 24, 2023

Developments

Lantheus, POINT Biopharma to commercialize PNT2002 & PNT2003

Lantheus Holdings (NASDAQ:LNTH) and POINT Biopharma Global (NASDAQ:PNT) announced a set of strategic collaboration agreements in which Lantheus would license exclusive worldwide rights to POINT’s PNT2002 and PNT2003...

November 14, 2022

Markets

SVB Leerink starts Lantheus at OP; PT $24

SVB Leerink launched coverage of Lantheus Holdings (NASDAQ:LNTH) with an “outperform” rating and $24 price target. The stock closed at $16.27 on Jan. 29. Lantheus is a leading player in diagnostic nuclear medicine...

February 1, 2021

Developments

FDA approves Lantheus’ VIALMIXRFID activation device

The FDA approved Lantheus’ (NASDAQ:LNTH) supplemental drug application for VIALMIXRFID, a device that activates the company’s DEFINITY injectable suspension. DEFINITY injectable suspension is an ultrasound imaging agent...

August 12, 2020

Tag - LNTH

Lantheus, POINT get FDA fast track for mCRPC

Lantheus, POINT Biopharma to commercialize PNT2002 & PNT2003

SVB Leerink starts Lantheus at OP; PT $24

FDA approves Lantheus’ VIALMIXRFID activation device

General

More